BRIEF published on 11/04/2024 at 11:51, 4 months 28 days ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 4 months 28 days ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 4 months 28 days ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 4 months 28 days ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 5 months 22 days ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 5 months 22 days ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 5 months 22 days ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 5 months 22 days ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 8 months 24 days ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 8 months 24 days ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 04/03/2025 at 05:10, 5 hours 56 minutes ago Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 9 hours 31 minutes ago GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 11 hours 31 minutes ago Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 15 hours 6 minutes ago Network-1 Announces Acquisition of Patent Portfolio
Published on 04/03/2025 at 09:00, 2 hours 5 minutes ago Partners Group to invest in Gestcompost, the largest organic waste manager in Spain, through a continuation fund
Published on 04/03/2025 at 09:00, 2 hours 5 minutes ago Upward trends in Europe – growing investor interest?
Published on 04/03/2025 at 08:30, 2 hours 35 minutes ago ALVAREZ & MARSAL CREATES LEADING CORPORATE FINANCE PRACTICE IN SWITZERLAND BY JOINING FORCES WITH AVELA CAPITAL LED BY STEPHAN BRÜCHER
Published on 04/03/2025 at 08:15, 2 hours 50 minutes ago 'CGTN: China-India ties at 75: 'Dragon-Elephant Tango' will benefit both'
Published on 04/03/2025 at 08:00, 3 hours 5 minutes ago SWEF: Full Year Results for the Year Ended 31 December 2024
Published on 04/03/2025 at 09:45, 1 hour 20 minutes ago GUILLEMOT CORPORATION: Information regarding the total number of voting rights and shares 31/03/2025
Published on 04/03/2025 at 09:45, 1 hour 20 minutes ago GUILLEMOT CORPORATION : Informations relatives au nombre total de droits de vote et d’actions 31/03/2025
Published on 04/03/2025 at 09:35, 1 hour 30 minutes ago Déclaration du nombre d’actions et droits de vote au 31 mars 2025
Published on 04/03/2025 at 09:35, 1 hour 30 minutes ago Disclosure of Share Capital and Voting Rights as of March 31, 2025
